MedTrace Logo

To Study the Absorption, Distribution, Metabolism and Excretion of AZD1305

NCT00689247 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of this study is to learn more about how AZD1305 is handled by the body, i.e the absorption, distribution, metabolism and excretion of AZD1305.

Conditions

  • Healthy

Interventions

DRUG

AZD1305

oral solution, single dose

DRUG

AZD1305

iv infusion, single dose

Sponsors & Collaborators

Principal Investigators

  • Helen Lunde, MD · AstraZeneca R&D, Mölndal, Sweden

  • Raj Chetty, MBBS, MD · AstraZeneca CPU Alderley Park, United Kingdom

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689247 on ClinicalTrials.gov